These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26916877)

  • 1. Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate.
    Dempster DW; Cosman F; Zhou H; Nieves JW; Bostrom M; Lindsay R
    J Bone Miner Res; 2016 Aug; 31(8):1518-26. PubMed ID: 26916877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.
    Cosman F; Nieves JW; Roimisher C; Neubort S; McMahon DJ; Dempster DW; Lindsay R
    Bone; 2019 Mar; 120():246-253. PubMed ID: 30355512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate.
    Cosman F; Nieves JW; Zion M; Garrett P; Neubort S; Dempster D; Lindsay R
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2769-76. PubMed ID: 25961136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao SD; Miller PD; Woodson GC; Lindsay R; Binkley N; Alam J; Ruff VA; Gallagher ER; Taylor KA
    J Bone Miner Res; 2016 Jul; 31(7):1429-39. PubMed ID: 26841258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment.
    Ma YL; Zeng QQ; Chiang AY; Burr D; Li J; Dobnig H; Fahrleitner-Pammer A; Michalská D; Marin F; Pavo I; Stepan JJ
    Bone; 2014 Feb; 59():139-47. PubMed ID: 24269280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.
    Hofstetter B; Gamsjaeger S; Varga F; Dobnig H; Stepan JJ; Petto H; Pavo I; Klaushofer K; Paschalis EP
    Osteoporos Int; 2014 Dec; 25(12):2709-19. PubMed ID: 25037600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
    J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ; Burr DB; Li J; Ma YL; Petto H; Sipos A; Dobnig H; Fahrleitner-Pammer A; Michalská D; Pavo I
    Osteoporos Int; 2010 Dec; 21(12):2027-36. PubMed ID: 20135094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients.
    Misof BM; Roschger P; Zhou H; Nieves JW; Bostrom M; Cosman F; Lindsay R; Klaushofer K; Dempster DW
    Bone Rep; 2020 Jun; 12():100253. PubMed ID: 32215284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping Bone Changes at the Proximal Femoral Cortex of Postmenopausal Women in Response to Alendronate and Teriparatide Alone, Combined or Sequentially.
    Whitmarsh T; Treece GM; Gee AH; Poole KE
    J Bone Miner Res; 2015 Jul; 30(7):1309-18. PubMed ID: 25639838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study.
    Dempster DW; Roschger P; Misof BM; Zhou H; Paschalis EP; Alam J; Ruff VA; Klaushofer K; Taylor KA
    J Bone Miner Res; 2016 Aug; 31(8):1527-35. PubMed ID: 26931279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.
    Yano T; Yamada M; Inoue D
    Calcif Tissue Int; 2017 Jul; 101(1):102-110. PubMed ID: 28337514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.
    Ma YL; Marin F; Stepan J; Ish-Shalom S; Möricke R; Hawkins F; Kapetanos G; de la Peña MP; Kekow J; Martínez G; Malouf J; Zeng QQ; Wan X; Recker RR
    Bone; 2011 May; 48(5):972-8. PubMed ID: 21262402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density.
    Muschitz C; Kocijan R; Fahrleitner-Pammer A; Lung S; Resch H
    J Bone Miner Res; 2013 Jan; 28(1):196-205. PubMed ID: 22836585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium.
    Lindsay R; Zhou H; Cosman F; Nieves J; Dempster DW; Hodsman AB
    J Bone Miner Res; 2007 Apr; 22(4):495-502. PubMed ID: 17227219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Teriparatide on Bone Formation in the Human Femoral Neck.
    Cosman F; Dempster DW; Nieves JW; Zhou H; Zion M; Roimisher C; Houle Y; Lindsay R; Bostrom M
    J Clin Endocrinol Metab; 2016 Apr; 101(4):1498-505. PubMed ID: 26900640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques.
    Paschalis EP; Krege JH; Gamsjaeger S; Eriksen EF; Burr DB; Disch DP; Stepan JJ; Fahrleitner-Pammer A; Klaushofer K; Marin F; Pavo I
    J Bone Miner Res; 2018 Dec; 33(12):2230-2235. PubMed ID: 30102789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study.
    Dempster DW; Zhou H; Ruff VA; Melby TE; Alam J; Taylor KA
    J Bone Miner Res; 2018 Apr; 33(4):627-633. PubMed ID: 29194749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial.
    Dempster DW; Zhou H; Recker RR; Brown JP; Bolognese MA; Recknor CP; Kendler DL; Lewiecki EM; Hanley DA; Rao DS; Miller PD; Woodson GC; Lindsay R; Binkley N; Wan X; Ruff VA; Janos B; Taylor KA
    J Clin Endocrinol Metab; 2012 Aug; 97(8):2799-808. PubMed ID: 22701017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.